Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for Organogenesis Holdings (ORGO) over the last 9 years, with Sep 2025 value amounting to $11.9 million.

  • Organogenesis Holdings' Change in Accured Expenses rose 623.82% to $11.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 59.22%. This contributed to the annual value of $9.2 million for FY2024, which is 192.03% up from last year.
  • Organogenesis Holdings' Change in Accured Expenses amounted to $11.9 million in Q3 2025, which was up 302.66% from -$5.9 million recorded in Q2 2025.
  • Over the past 5 years, Organogenesis Holdings' Change in Accured Expenses peaked at $11.9 million during Q3 2025, and registered a low of -$8.0 million during Q1 2025.
  • Moreover, its 3-year median value for Change in Accured Expenses was -$938,000 (2023), whereas its average is $941,727.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 400.85% in 2022, then spiked by 623.82% in 2025.
  • Over the past 5 years, Organogenesis Holdings' Change in Accured Expenses (Quarterly) stood at $2.6 million in 2021, then plummeted by 400.85% to -$7.8 million in 2022, then skyrocketed by 35.28% to -$5.0 million in 2023, then spiked by 165.11% to $3.3 million in 2024, then surged by 623.82% to $11.9 million in 2025.
  • Its Change in Accured Expenses was $11.9 million in Q3 2025, compared to -$5.9 million in Q2 2025 and -$8.0 million in Q1 2025.